Chromosome 17q is frequently rearranged in breast cancer. Allelotyping studies have proposed the existence of at least four regions of allelic imbalance (AI). Here we present a study combining allelotyping using 19 CA repeat markers mapping in the 17q21 ± 25 region and molecular cytogenetics (CGH and FISH). Allelotyping was undertaken on 178 pairs of cognate tumor and normal DNA in order to determine the number of regions of AI and de®ne the shortest overlaps. AI ranged from 34 ± 54% of the informative cases according to the marker and, overall, 66% of the tumors presented AI at one of the markers tested. Analysis of the patterns of imbalances revealed at least ®ve common regions of imbalance respectively de®ned by markers: D17S855, which is intragenic of BRCA1 (SRO 1), D17S1607 (SRO 2), D17S1855 (SRO 3), between D17S789 and D17S785 (SRO 4) and D17S784 (SRO 5). In order to characterize the nature of the genetic events revealed by allelotyping we performed CGH analysis on a subset of 43 tumors presenting variable patterns of imbalance. CGH showed that AI at 17q could represent four dierent types of genetic events: loss of chromosome 17, gain of 17q, gain of 17q22 ± q24, loss of 17q11 ± q21 and/ or 17q25 ± qter. Some of these anomalies could occur concomitantly within the same tumor. Since 35% of the tumors analysed by CGH presented gains, these data indicated that AI at 17q were not solely indicative of losses of genetic material and could also represent DNA ampli®cation. Gains were most commonly observed in the 17q23 ± q24 regions. This suggested that AI in SRO 2 and SRO 3 corresponded to DNA ampli®cation. To assess this, we isolated BAC clones by PCR screening for markers D17S1607 and D17S1855 and used these in FISH experiments on six breast tumor cell lines and 14 breast cancer specimens. FISH results showed that both D17S1607 and D17S1855 were frequently involved in DNA ampli®cation (8 ± 30 copies). Altogether, our data show that allelotyping can be eciently used in amplicon mapping. Clinico-pathological correlations indicated that imbalance at 17q preferentially occurred in high grade, PR-and ERBB2 ampli®ed tumors.
Introduction
The long arm of chromosome 17 is a frequent target of cancer associated genetic anomalies. It, indeed, harbors recurrent chromosomal breakpoints, involved in balanced and unbalanced rearrangements (Mitelman et al., 1997) , and a large body of literature has shown the existence of several regions of DNA ampli®cation and interstitial deletions (Foulkes et al., 1993; Jacobs et al., 1993) . A number of known cancer genes map to chromosome 17q, among which ERBB2, BRCA1 and NME1 have been shown to be most frequently involved in breast cancer. Whereas, ERBB2, localized at 17q12 ± q21, is known to be ampli®ed at high levels , BRCA1 and NME1, both mapping at 17q21, correspond to regions of chromosomal losses (Cropp et al., 1993; Munn et al., 1996; Niederacher et al., 1997; Rajah et al., 1997) . The number of regions showing allelic imbalance (AI) has increased along with the number and the informativeness of available polymorphic markers. Combining results presented in two recent studies leads to conclude to the existence of at least four regions of allelic imbalance along 17q, one at 17q21, two in the 17q22 ± q24 region and one at 17q25 (Niederacher et al., 1997; Plummer et al., 1997b) . However, the nature of the anomalies involving these regions remains uncertain. Chromosome transfer studies have clearly associated a growth inhibiting potential to the 17q25 portion, thus supporting the occurrence of losses in this region. As shown by comparative genomic hybridization (CGH) gains in the 17q22 ± q24 region are frequent in breast tumors Isola et al., 1995; Muleris et al., 1994; Ried et al., 1995) and recently BaÈ rlund et al. (1997) have demonstrated that 17q22 ± q24 gains corresponded to the amplification of two separate subregions.
In order to determine the nature of the genetic events aecting the respective regions of AI detected on 17q in breast cancer we analysed a series of 178 breast tumors using 19 CA repeat mapping from 17q21 ± 17q25. Our allelotyping data are indicative of the existence of at least ®ve regions of AI. A subset of tumors was subsequently studied by CGH and FISH in order to determine the nature of the genetic events involved.
Results

Allelotyping of chromosome 17q in breast tumors
We analysed 178 pairs of breast tumor and cognate normal DNA (Table 1) with 19 CA repeat markers mapping in the 17q21 ± q25 region (Table 2) . Sixteen out of the 19 markers belonged to the GeÂ neÂ thon collection and were chosen according to their relative localizations. Three markers D17S1323, D17S1327 and D17S1306 were not part of the GeÂ neÂ thon set and were positioned according to information stored in GDB. We noted discrepancies for some blocks of markers between the GeÂ neÂ thon order and positions reported in the literature. This was particularly true for the block composed of D17S1604, D17S794, D17S948 which were mapped as follows by Plummer and coworkers D17S1604, D17S948, D17S794 (Plummer et al., 1997c) . We analysed our AI data using both combinations and adopted the order proposed by Plummer. The order of the markers and their relative chromosomal localizations are as shown in Figure 1 . Frequency of allelic imbalances ranged from 34.3 ± 54.2% according to the marker (Table 2 ). Markers presenting the highest incidence of AI were D17S855 (localized in an intron of the BRCA1 gene) with 54.2%, D17S809 42.7%, D17S1306 45.3%, D17S1855 42.8%, and D17S789 41.3%. Overall 118/178 (66.2%) of the tumors showed AI at one 17q marker at least. Only a minority of the tumors presented AI at all the informative markers tested (19/178), while the rest (99) presented either focal AI (AI involving only one, at most two adjacent markers,¯anked by heterozygous markers) or complex zebra patterns (Figure 1 ).
Regions of overlap
Two criteria were used to de®ne common regions of imbalance. At ®rst we identi®ed the markers most frequently involved in AI (Table 2) . In a second step, we searched for common regions of AI¯anked by markers conserving heterozygosity. There was an overall good correspondence between peaks of AI and regions of overlap, except for D17S809, whose imbalance was dicult to distinguish from that occurring at neighboring regions. We, accordingly, de®ned ®ve common domains of imbalance. These corresponded, from centromere to telomere, to D17S855-D17S1327 (SRO 1), D17S1306-D17S1607 (SRO 2), D17S1835-D17S1855 (SRO 3), D17S789-D17S785 (SRO 4), D17S784 (SRO 5) (Figures 1 and  5) . SRO 1 could easily be de®ned because of ®ve tumors presenting AI at D17S855 and/or D17S1323 and in which either D17S1327 or D17S941 remained heterozygous. However, patterns observed in three tumors (Figure 1 , rows 4, 5 and 10) suggest that this region may be split into two subregions. The centromeric limit of SRO 2 was de®ned by eight tumors retaining heterozygosity at D17S787 and showing imbalance at D17S1306 (Figure 1 , rows 12 ± 19). The telomeric boundary could be deduced from the imbalance pattern shown by four tumors (Figure 1 , rows 18 ± 21) and was set at D17S1607. However, two tumors presenting focal AI at D17S1607 suggest that this SRO could be narrowed down to an interval comprized between D17S1306 and D17S1604. SRO 3 could be delimited at its centromeric end by D17S1835, as suggested by four tumors heterozygous at D17S1604 and showing imbalance at either D17S1835 or D17S1855 ( Figure  1 , rows 26 ± 29). The telomeric limit was de®ned by six tumors heterozygous at D17S948, while showing AI at more centromeric markers (Figure 1 , rows 24 ± 25, 29 ± 31). However, one tumor presenting focal AI at D17S1855 supports the notion that SRO 3 could be centered around this marker (Figure 1, row 30) . SRO 4 was de®ned by markers D17S789 and D17S785 (Figure 1 , rows 34 ± 47). However, tumors showing AI at D17S789 while retaining heterozygosity at D17S785 (Figure 1 , rows 34 ± 37) and cases presenting AI at D17S785 and a heterozygous pattern at D17S789 (Figure 1 , rows 46 ± 47) suggested that this region of imbalance was localized in between these two markers further narrowing the SRO. SRO 5 was de®ned by D17S784 as suggested by four tumors showing heterozygosity at D17S939, however, because D17S784 was our most distal marker we could not propose any telomeric boundary ( Figure 1 , rows 48 ± 55).
Correspondence between allelotyping and CGH data
We selected 
FISH analysis
In order to assess whether SRO 2 and SRO 3 corresponded to a gain or a loss, we isolated genomic clones by PCR screening of a BAC library. Two clones, corresponding to markers D17S1607 and D17S1855 respectively, were isolated and their chromosomal localization veri®ed ( Figure 4a ). As shown by dual color FISH both clones map at 17q23 ± q24 in close proximity of each other. Hybridization on metaphase chromosomes prepared from breast cancer cell lines revealed that both BAC clones were ampli®ed at varying levels in 4/6 cell lines tested (Table 3) . In most cases both probes revealed equivalent levels of ampli®cation except in MCF7 cells where BAC 23E14 (D17S1855) presented twice as much copies than BAC 215L21 (D17S1607). Furthermore, we noted that in cell lines presenting an elevated number of centromeres 17, such as BT474 and SKBR3, the centromeric signals and that of both BAC clones were not systematically colocalized on the same chromosome ( Figure 4b, c,d ). This suggested that ampli®cation of the 17q23 ± q24 region and polyploidization of chromosome 17 could occur independently. We performed interphase FISH on 14 tumors for which tissue was available and whose AI and CGH pro®les had been previously determined (Figure 2 ). Eleven out of these 14 tumors presented gains on 17q by CGH and eleven showed elevated copy numbers with either BAC clone upon FISH analysis (Figures 2 and 4) . The three remaining tumors corresponded to cases showing a loss at 17q (partial or total) or no event in the CGH analysis ( Figure 2 , rows 5, 32, 41). One out of these three tumors presented nevertheless elevated copy numbers with both BAC clones. It was remarkable that this tumor presented a variable number of centromeric signals suggesting intratumoral heterogeneity (Figure 2 , row 5). We also noted that BAC 215L21 (D17S1607) was more frequently ampli®ed, and at higher levels, than BAC 23E14 (D17S1855). Heterozygosity is depicted by a white square, AI by a black square and homozygosity (non-informative) has been left in blank. Common regions of imbalance are indicated by black frames and within these frames shaded areas correspond to actual losses
Correlations with clinico-pathological parameters
The allelic imbalance status of every marker was correlated with the clinico-pathological characteristics and available molecular data. Correlations were calculated using the w 2 test. Interestingly, only markers previously identi®ed as hot spots for regions of imbalance presented correlations with clinicopathological parameters (Table 4 ). The most frequently observed correlation (10/19 markers) was with high tumor grade and this could be combined, for three and ®ve markers respectively, to loss of progesterone receptor or histological type. Variations of signi®cance (testi®ed by the P values and w 2 values) were noted according to the marker and overall these data strongly suggest that anomalies aecting the long arm of 17 occur preferentially in aggressive breast cancer. We searched for associations with amplifications of the 11q13 region (CCND1 and EMS1 genes), ERBB2, FGFR1, MYC and 20q13. Interestingly correlation was only found with ERBB2, which maps at 17q12-q21 (Table 4) .
Discussion
In this work we studied genetic alterations on 17q in breast tumors by two convergent approaches: allelotyping with 19 CA repeat markers and molecular cytogenetics (CGH and FISH). We concentrated our Figure 1 . Tumors below the gray shaded line correspond to discordance between CGH and AI. Framed areas of AI indicate the correspondence between gains in the 17q23 ± 24 region and AI at either SRO 2 or SRO 3. A subset of 14 tumors was then studied by interphase FISH on tumor touch preparations using a probe to centromere 17 and two BAC clones 215L21 and 23E14 respectively containing CA repeat markers D17S1607 and D17S1855. Numbers in the corresponding columns indicate the numbers of signals observed in tumor nuclei. Several numbers or ranges indicate intratumoral heterogeneity. Non analysed specimens were left in blank eorts on the portion comprised between 17q21 (BRCA1) and 17q25. Our aim was double: (1) map common regions of allelic imbalance and, in some cases, reduce the size of the overlaps; (2) determine the nature of the imbalances; chromosomal losses or copy number gains. As a matter of fact, allelic imbalances have generally been considered as the expression of losses of genetic material, but using this technique it is dicult to dierentiate an under-representation of one allele (loss) from the over-representation (gain) of the other one. It has indeed been proposed that allelic imbalances on 17q could in some cases correspond to gains (Devilee et al., 1991) . Furthermore, recent work has shown that allelotyping based on CA repeat analysis has been used successfully in amplicon mapping of tumors known to be ampli®ed at 12q13 (Wolf et al., 1997) , as well as in characterizing chromosome duplication (Bugert et al., 1998; Kenck et al., 1997) .
De®nition of common regions of imbalance
We concluded to the existence of ®ve discrete regions of imbalance respectively de®ned, from centromere to telomere, by D17S855-D17S1327 (SRO 1), D17S1306-D17S1607 (SRO 2), D17S1835-D17S1855 (SRO 3), D17S789-D17S785 (SRO 4), D17S784 (SRO 5). These domains had to ®t two criteria; correspond to a region of LOH commonly¯anked by heterozygous markers and represent a peak of imbalance. Using only the ®rst criterion we could have de®ned one additional domain represented by D17S807, but this did not correspond to a peak of imbalance. Alternatively, D17S1327 and D17S809 corresponded to peaks of AI. Concerning D17S1327, it is noticeable that our data suggest that SRO 1 may be split into two subregions, one, centromeric, centered on D17S855 and the second, in a more telomeric position, represented by D17S1327. While the centromeric subregion seems to correspond to BRCA1, there is, at present, no good candidate target gene for the second domain and allelotyping data needs to get enriched to conclude on its precise localization. For this reason we kept our conclusion somewhat conservative and de®ned only one SRO. Concerning D17S809, only a limited number of tumors showed a pattern of AI ®tting the criterion of a common domain of imbalance.
The localizations of the SROs de®ned in this study are in good concordance with previously reported data ( Figure 5 ). Indeed, de®nition of SRO 2 and SRO 3 is coherent with that of Plummer et al. (1997b) . Using slightly dierent sets of markers this group concluded to the existence of two domains of imbalance which they localized in close proximity to ours. Their core regions were delimited by D17S787 (centromeric of D17S1607) and by D17S948 (telomeric of D17S1855). Data for SRO 4 and SRO 5 required more interpretation. We had delimited SRO 4 between D17S789 and D17S785, which correspond to a 16 cM overlap. Combining results by Plummer et al. (1997a) , which conclude to the existence of a common domain between D17S949 and D17S1301, and those of Kalikin et al. (1997) , who describe a core region represented by D17S937, it could be that our SRO 4 overlaps two regions of imbalance. In our dataset SRO 5 was best de®ned by D17S784, which corresponded to the most telomeric marker used in our study. This latter region was separated from SRO 4 by D17S939, which interestingly corresponds to a region proposed to contain a tumor suppressing activity in chromosome transfer experiments (Theile et al., 1995) . We have no explanation for these discrepancies and think that further allelotyping is required in this portion of 17q in order to reach a precise de®nition of all regions of imbalance in presence.
Molecular cytogenetics study
Dierent experimental evidences converge to strongly suggest that SRO 1, SRO 4 and SRO 5 correspond to chromosomal losses. Indeed, SRO 1, which maps at 17q21, is known to comprise BRCA1 and other tumor suppressing genes, while SRO 4 and SRO 5 map at 17q25 and could correspond to growth inhibiting activities observed in chromosome transfer experiments. These conclusions are reinforced by published CGH data, as well as that presented here, showing frequent loss of either region. On the other hand, events in the central portion of 17q remained unsure as CGH analysis had shown frequent gains in the 17q22 ± q24 region Isola et al., 1995) . Furthermore, the complexity of AI patterns was indicative of intense rearrangements in this portion of chromosome 17 and we were interested to get more insight on the nature of these genetic events revealed by allelotyping. Our CGH analysis of a selected set of tumors revealed that AI at 17q could correspond to events dierent in nature such as; (i) loss of chromosome 17, (ii) gain of the whole 17q, (iii) loss of 17q11 ± q21 and/or 17q25 ± qter, (iv) gain at 17q22 ± q24. Some tumors were found to harbor combinations of losses and gains and these corresponded to cases showing complex zebra patterns. Most tumors showing gains in the 17q22 ± q24 region presented AI either in SRO 2 or SRO 3. This strongly suggested that AI in both these SROs represented DNA ampli®cation. To bring direct evidence of this we isolated BAC clones corresponding to core markers of SRO 2 and SRO 3 and performed FISH experiments on breast cancer cell lines and breast tumor specimens. Four out of six cell lines and 10/14 tumors tested showed elevated copy numbers with both BAC clones. These results thus bring direct evidence that SRO 2 and SRO 3 correspond to DNA ampli®cation and are in agreement with data by BaÈ rlund and coworkers (BaÈ rlund et al., 1997). These ®ndings bear two interesting implications: (1) allelotyping can be eciently used for amplicon mapping; (2) AI observed on a number of chromosomal sites in breast cancer could in fact correspond to gains of genetic material. This may explain the discrepancy shown between allelotyping and CGH studies on chromosome 1q, where multiple SROs have been described while CGH showed the existence of several regions of gains (Benitez et al., 1997; Isola et al., 1995; Kuukasjarvi et al., 1997; Munn et al., 1995) .
We observed some discordance between CGH and AI data. This could be due to dierences in resolution and sensitivity of both approaches. CGH has limited spatial resolution and quantitative changes are only detected in case they involve relatively large regions of DNA (10 Mb for losses and 1 ± 3 Mb for gains depending on the level of ampli®cation) (Forozan et Figure 5 Schematic representation of regions of imbalance observed on 17q in breast cancer. Black bars show our data, black lines regions reported in the literature. 1: Kalikin et al., 1997 , 2: Plummer et al., 1997a , 3: Plummer et al., 1997b , 4: Niederacher et al., 1997 . Markers have been ordered according to data stored in GDB (http//:www.infobiogen.fr) and the scale is indicated in cM. Cytogenetic banding indications on the left are relative. Markers used in this study are shown in bold, those corresponding to the literature in italic al., 1997). This could explain some of the discordances. Because we performed our allelotyping analysis using an automated sequencer, which allows a quanti®cation of the signal, it could be that a number of low level imbalances, were beyond the detection range of CGH.
Clinico-pathological correlations
Our search for clinico-pathological correlations revealed two interesting ®ndings: (1) AI at 17q preferentially occurred in a subset of aggressive breast tumors, as illustrated by correlation with high tumor grade and loss of PR; (2) Correlations were strongest with markers representing the core of the SROs and most signi®cant correlations were observed with SRO 2 and SRO 3. Associations with other genetic anomalies also bore interesting information. As a matter of fact AI at SRO 1 and SRO 3 correlated with the ampli®cation of ERBB2 to the exclusion of any other event. We were interested to see that AI at SRO 3, which we show to correspond to DNA ampli®cation, presented the strongest association with the ampli®cation of the ERBB2 gene which maps at 17q21.1. This con®rmed our previous observations which showed that gains at 17q preferentially occurred in a subset of aggressive breast tumors showing frequent ampli®cation of ERBB2 .
Material and methods
Tumor and blood samples 178 breast tumors and cognate blood samples were collected at the Cancer Center of Montpellier (France). Description of the tumor series is given in Table 1 . Tumor biopsies were snap-frozen in liquid nitrogen upon surgical removal and stored at 7808C until DNA extraction. White-cell nuclei were isolated from blood by hypotonic lysis of red cells. These were stored frozen until DNA was extracted.
Cell lines
MDA-MB-134, MDA-MB-157, MCF7, ZR75-1 and SKBR3 were maintained in our laboratory. BT474 was a generous gift from Dr F Vignon (INSERM U 148, Montpellier).
DNA isolation
Genomic DNAs were extracted using standard phenol/ chloroform procedure adapted to a nucleic acid extraction robot (Applied Biosystems, St Quentin-en-Yveline, France).
Microsatellite markers
Primer sequences and all information for the 19 microsatellite markers are available from Genome DataBase (John Hopkins University School of Medicine, Baltimore, MD, USA (http//gdb.infobiogen.fr). All 19 markers map at chromosome 17q in the 17q21-qter range (Table 2) . Oligonucleotide primers were obtained from Isoprim (Toulouse, France). The reverse primers were labeled at the 5-end using three dierent¯uorescent dyes (Hex, Fam, Tet) . PCR reactions were prepared in 96 wells microtiter plates, in a total reaction volume of 12.5 ml containing 10 pmoles of each primer, 1.5 mM MgCl2, 100 mM of each dNTPs, 0.5 U of AmpliTaq Gold (Perkin Elmer) and 15 ± 20 ng of DNA. Microtiter plates were sealed using rubber lids. PCR reaction were run on a Hybaid touchdown thermal-cycler equipped with heating lids. PCR conditions were as follows: 1 cycle of denaturation at 948C for 9.5 min followed by 35 cycles: denaturation at 948C for 30 s, annealing 50 to 658C for 30 s, elongation at 728C for 30 s, followed by a ®nal extension step for 7 min at 728C.
Analysis of PCR products
PCR products were analysed on 4% polyacrylamide denaturing gels in 1X TBE buer. Gels were run and data collected on an automated ABI 377 DNA sequencer (Perkin Elmer). Three PCR products corresponding to dierent markers ampli®ed from an identical sample were mixed in equal quantity and 0.7 ml of this mix were added to 2 ml of loading buer (70% formamide, 25 mM EDTA, 50 mg/ml blue dextran) containing Genescan 350-TAMRA (Perkin Elmer)¯uorescently labeled size standards. This mix was denatured for 5 min at 948C, placed on ice and loaded onto the preheated gel (518C). Gels were routinely run for 2 h at 3000 V. Data were collected automatically, analysed and quanti®ed using the Genescan 2.1 software (Perkin Elmer), meaning that sizes of the fragments and the heights of the peaks were calculated.
Allellic imbalance assessment
Homozygosity was classi®ed as non-informative. Allelic imbalance was determined by comparing the ratio of allele peak heights in tumor and control DNA. The ratio Rt=At/ Bt was determined for the tumor DNA and for the matched blood sample DNA Rn=An/Bn, then the level of allelic imbalance was calculated according to the equation 1-Rt/Rn giving a value ranging from 0.00 ± 1.00. If Rt/Rn was superior to 1.00 the equation was converted to 1-Rn/Rt. A value of 0.7 meant a signal reduction of 70% of one allele. Allelic imbalance was considered above a limit of 20% of signal reduction. Samples presenting AI were routinely run twice and only those which could be reproduced in all experiments were included in the study. Reproducibility was of 95%.
CGH
Metaphase preparation, genomic DNA labeling, CGH reaction and images analysis were as previously described .
BAC clone isolation
BAC clones were isolated by PCR screening using primers for markers D17S1607 and D17S1855. The human genomic BAC library was purchased from Genome Systems Inc. (St Louis, MI, USA) and positive pools ordered from the supplier. Procedures were as described by the supplier.
FISH
Normal metaphase chromosomes were prepared from umbilical cord blood according to standard cytogenetic protocols. Metaphase from cancer cell lines were done as described by Fletcher (1994) . FISH on metaphase and interphase chromosomes, as well as tumor touch preparation were done as shown in Bautista and Theillet (1998) .
Microscopy and digital image analysis
This was done as described previously .
Statistical analysis
Correlation studies were performed using the EpiInfo 3.0 software package from CDC (Atlanta, GA, USA) for Chi 2 tests.
